Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Nippon Kayaku Co., Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Nippon Kayaku Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Nippon Kayaku Co., Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Nippon Kayaku Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Nippon Kayaku Co., Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Nippon Kayaku Co., Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Nippon Kayaku Co., Ltd.'s pipeline products Reasons to buy - Evaluate Nippon Kayaku Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Nippon Kayaku Co., Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Nippon Kayaku Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Nippon Kayaku Co., Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nippon Kayaku Co., Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Nippon Kayaku Co., Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Nippon Kayaku Co., Ltd. Snapshot 5 Nippon Kayaku Co., Ltd. Overview 5 Key Information 5 Key Facts 5 Nippon Kayaku Co., Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Nippon Kayaku Co., Ltd. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Nippon Kayaku Co., Ltd. - Pipeline Products Glance 13 Nippon Kayaku Co., Ltd. - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Phase III Products/Combination Treatment Modalities 14 Nippon Kayaku Co., Ltd. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Nippon Kayaku Co., Ltd. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Nippon Kayaku Co., Ltd. - Drug Profiles 17 infliximab biosimilar 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 paclitaxel 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 apaziquone 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 fentanyl 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 NK-012 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ozarelix 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 NK-314 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 trastuzumab biosimilar 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Nippon Kayaku Co., Ltd. - Pipeline Analysis 30 Nippon Kayaku Co., Ltd. - Pipeline Products by Target 30 Nippon Kayaku Co., Ltd. - Pipeline Products by Route of Administration 32 Nippon Kayaku Co., Ltd. - Pipeline Products by Molecule Type 33 Nippon Kayaku Co., Ltd. - Pipeline Products by Mechanism of Action 34 Nippon Kayaku Co., Ltd. - Recent Pipeline Updates 36 Nippon Kayaku Co., Ltd. - Dormant Projects 41 Nippon Kayaku Co., Ltd. - Company Statement 42 Nippon Kayaku Co., Ltd. - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables Nippon Kayaku Co., Ltd., Key Information 5 Nippon Kayaku Co., Ltd., Key Facts 5 Nippon Kayaku Co., Ltd. - Pipeline by Indication, 2014 8 Nippon Kayaku Co., Ltd. - Pipeline by Stage of Development, 2014 9 Nippon Kayaku Co., Ltd. - Monotherapy Products in Pipeline, 2014 10 Nippon Kayaku Co., Ltd. - Partnered Products in Pipeline, 2014 11 Nippon Kayaku Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12 Nippon Kayaku Co., Ltd. - Pre-Registration, 2014 13 Nippon Kayaku Co., Ltd. - Phase III, 2014 14 Nippon Kayaku Co., Ltd. - Phase II, 2014 15 Nippon Kayaku Co., Ltd. - Preclinical, 2014 16 Nippon Kayaku Co., Ltd. - Pipeline by Target, 2014 31 Nippon Kayaku Co., Ltd. - Pipeline by Route of Administration, 2014 32 Nippon Kayaku Co., Ltd. - Pipeline by Molecule Type, 2014 33 Nippon Kayaku Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 35 Nippon Kayaku Co., Ltd. - Recent Pipeline Updates, 2014 36 Nippon Kayaku Co., Ltd. - Dormant Developmental Projects,2014 41 Nippon Kayaku Co., Ltd., Subsidiaries 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.